The U.S. Food and Drug Administration today announced two major steps as part of an initiative to advance the implementation of real-time clinical trials (RTCT). First, the agency unveiled the ...

HERVolution Therapeutics, a biotechnology company pioneering human endogenous retrovirus (HERV)-targeting immunotherapies for oncology, metabolic diseases, and longevity, today announced the ...

The FDA today announced a new initiative to allow its reviewers to access information from clinical trials in real time, with ...

Voucher application details focus on AUD as a major driver of the U.S. substance use crisis and the genetic targeting of AD04 ...

The U.S. Food and Drug Administration is planning to launch a pilot program aimed at advancing real-time clinical trials ...

Ahead of Biomed Israel, Ittai Harel highlights a growing cohort of companies leveraging AI and data science tools to ...

Rare disease research operates under conditions of extreme complexity. These pressures are driving new approaches to evidence ...

An FDA initiative to implement real-world clinical trials could dramatically accelerate the pace at which new treatments ...

Over the past several years, pharmaceutical companies have been steadily integrating artificial intelligence (AI) into many aspects of clinical development. Today, AI’s impact is being felt from the ...

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, outlines future steps for the clinical development of rilzabrutinib, as well as promising data to advance to phase 3 studies ...

PALO ALTO, Calif.--(BUSINESS WIRE)--Science Exchange, the leading SaaS provider of supplier orchestration solutions for the life sciences industry, today announced the launch of its Clinical ...

TOS-358 is a covalent, pan-mutant, α-specific PI3K inhibitor designed to address key limitations of existing PI3Kα therapies which include limited mutation coverage and poor tolerability ...